PPARG and idiopathic pulmonary fibrosis: Importantly, it has been demonstrated that peroxisome proliferator-activated receptor gamma (PPARγ) activation induced the transdifferentiation of (myo)fibroblast to lipofibroblast [22], indicating that PPARγ agonists might be beneficial in treating IPF.